HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Sept. 20, 2022 (HealthDay News) -- Psoriatic arthritis (PsA) screening is acceptable to patients with psoriasis whether they are diagnosed with PsA or not, according to a research letter published online Aug. 17 in the British Journal of Dermatology.
Christine A. Silverthorne, from the University of the West of England in Bristol, and colleagues sought to understand the experience of screening from the perspective of 21 participants with psoriasis. Screening included an examination of skin, joints, hands, feet, scalp, physical tests (e.g., touching toes), height and weight measurement, blood tests, X-rays, magnetic resonance imaging scans, and questionnaires.
The researchers identified three main themes. First, screening was perceived as well-conducted and, overall, a positive and reassuring experience. Participants reported appreciating the thoroughness of the examination and the time to talk with specialists. Secondly, screening provided participants a sense of control over their health. Among those screening positive for PsA, they valued the help they were given in treating their condition, while those screening negative gained an awareness of symptoms for which to watch out. Lastly, participants suggested improvements to the screening process, including using case studies, signposting to support groups, and providing information. They also indicated barriers to screening, which included location, parking, and time of appointments.
"This qualitative study indicates that screening is acceptable and a potentially valuable method to increase the early detection of PsA in patients with psoriasis and improve their clinical outcomes," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Published on September 20, 2022